Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAPK14_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAPK14_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAPK14_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAPK14_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAPK14_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAPK14_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000717815 | Prostate | Tumor | transmembrane receptor protein serine/threonine kinase signaling pathway | 90/3246 | 355/18723 | 7.93e-05 | 8.19e-04 | 90 |
GO:000961214 | Prostate | Tumor | response to mechanical stimulus | 60/3246 | 216/18723 | 8.45e-05 | 8.46e-04 | 60 |
GO:000600613 | Prostate | Tumor | glucose metabolic process | 55/3246 | 196/18723 | 1.22e-04 | 1.14e-03 | 55 |
GO:004277012 | Prostate | Tumor | signal transduction in response to DNA damage | 49/3246 | 172/18723 | 1.87e-04 | 1.65e-03 | 49 |
GO:000931415 | Prostate | Tumor | response to radiation | 109/3246 | 456/18723 | 1.94e-04 | 1.70e-03 | 109 |
GO:004230612 | Prostate | Tumor | regulation of protein import into nucleus | 22/3246 | 60/18723 | 2.71e-04 | 2.24e-03 | 22 |
GO:003461217 | Prostate | Tumor | response to tumor necrosis factor | 66/3246 | 253/18723 | 2.87e-04 | 2.32e-03 | 66 |
GO:007259315 | Prostate | Tumor | reactive oxygen species metabolic process | 63/3246 | 239/18723 | 2.87e-04 | 2.32e-03 | 63 |
GO:004269213 | Prostate | Tumor | muscle cell differentiation | 93/3246 | 384/18723 | 3.45e-04 | 2.73e-03 | 93 |
GO:004578611 | Prostate | Tumor | negative regulation of cell cycle | 93/3246 | 385/18723 | 3.79e-04 | 2.95e-03 | 93 |
GO:001810513 | Prostate | Tumor | peptidyl-serine phosphorylation | 78/3246 | 315/18723 | 4.95e-04 | 3.66e-03 | 78 |
GO:000181914 | Prostate | Tumor | positive regulation of cytokine production | 109/3246 | 467/18723 | 4.98e-04 | 3.67e-03 | 109 |
GO:005087818 | Prostate | Tumor | regulation of body fluid levels | 91/3246 | 379/18723 | 5.37e-04 | 3.91e-03 | 91 |
GO:001021215 | Prostate | Tumor | response to ionizing radiation | 42/3246 | 148/18723 | 5.67e-04 | 4.10e-03 | 42 |
GO:004592715 | Prostate | Tumor | positive regulation of growth | 66/3246 | 259/18723 | 5.73e-04 | 4.13e-03 | 66 |
GO:003806613 | Prostate | Tumor | p38MAPK cascade | 20/3246 | 55/18723 | 5.74e-04 | 4.13e-03 | 20 |
GO:00456485 | Prostate | Tumor | positive regulation of erythrocyte differentiation | 14/3246 | 33/18723 | 6.47e-04 | 4.60e-03 | 14 |
GO:007135617 | Prostate | Tumor | cellular response to tumor necrosis factor | 59/3246 | 229/18723 | 8.15e-04 | 5.51e-03 | 59 |
GO:000268314 | Prostate | Tumor | negative regulation of immune system process | 101/3246 | 434/18723 | 8.70e-04 | 5.85e-03 | 101 |
GO:003017813 | Prostate | Tumor | negative regulation of Wnt signaling pathway | 46/3246 | 170/18723 | 9.84e-04 | 6.37e-03 | 46 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
hsa0501418 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SORAFENIB | SORAFENIB | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL585902 | AMG-548 | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3544930 | SC-80036 | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GEFITINIB | GEFITINIB | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | RHAMNETIN | RHAMNETIN | 24397781 |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | OPHIOBOLIN O | OPHIOBOLIN O | 22130129 |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2107779 | SEMAPIMOD | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565642 | RALIMETINIB | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1766582 | R-1487 | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | OSI-632 | OSI-632 | |